AH
AZN icon

Andreas Halvorsen’s AstraZeneca AZN Stock Holding History

Andreas Halvorsen’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,429,565
Closed -$78.1M – 66
2016
Q4 		$78.1M Sell
1,429,565
-658,229
-32% -$37.4M 0.35% 49
2016
Q3 		$137M Buy
+2,087,794
New +$136M 0.59% 35

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Andreas Halvorsen's AZN Position: Q1 2017 in Review

Andreas Halvorsen sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 1,429,565 shares — an estimated $78.1M sold.

Andreas Halvorsen first reported a position in AZN in Q3 2016 and held it in 2 quarters. The position peaked at $137M in Q3 2016. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

  • Andreas Halvorsen reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
  • Andreas Halvorsen sold 1,429,565 AstraZeneca shares in Q1 2017, an estimated $78.1M.
  • Andreas Halvorsen first reported a position in AstraZeneca in Q3 2016 and held it in 2 quarters.
  • Andreas Halvorsen's AstraZeneca position peaked at $137M in Q3 2016.
  • 461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Viking Global Investors's 13F filing for Q1 2017, filed 15 May 2017.